MedTrace Logo

Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome

NCT07780565 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-08-21

No results posted yet for this study

Summary

The goal of this clinical research study is to find the recommended dose of monzosertib in patients with relapsed/refractory AML and high-risk MDS. The safety and effects of monzosertib will also be studied.

Conditions

Interventions

DRUG

Monzosertib

Give by mouth

DRUG

Posaconazole

Given by mouth

DRUG

Isavuconazole

Given by mouth

Sponsors & Collaborators

  • Carna Biosciences, Inc.

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Abhishek Maiti, MBBS · UT MD Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-01-01
Primary Completion
2029-08-30
Completion
2031-08-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07780565 on ClinicalTrials.gov